NCI Awards Insightful $1.4M in Contracts to Develop Proteomic Software
Statistical software developer Insightful said this week that the National Cancer Institute has awarded it two Phase II contracts worth $1,394,027 to develop proteomics software.
Under the terms of the two-year contracts, Insightful will develop software for identifying protein biomarkers and will also develop a product called S+Proteome for processing and analyzing protein mass spectral data.
The awards follow on two preliminary software-development contracts worth $186,000 that NCI awarded Insightful in February [BioInform 02-10-06].
S+Proteome will be built upon Insightful's S-Plus and S+ArrayAnalyzer software products.
As part of the phase II contracts, Insightful said it will also write a book on the analysis of mass spectra data using S-Plus and S+Proteome.
Crystallographers Form Consortium to Support Interoperability of Synchrotron Data
A nascent effort is underway in the protein crystallography community to ensure interoperability of synchrotron data.
The consortium, called MEDSBIO (Management of Experimental Data in Structural Biology), will address the "interface issues" that arise from dealing with multiple data-management protocols, said Herbert Bernstein, professor of computer science at Dowling College, who is spearheading the effort.
"The situation we're getting into at newer beam lines as the light source ability to do protein crystallography expands around the world is that people are finding themselves having to deal with the interfaces between multiple beam line standards, multiple ways of doing things," Bernstein told BioInform. "The objective of MEDSBIO is not to tell somebody they have to do something different than what works for them where they are, but to work on the interfaces so that people can cope with the fact that there are different approaches at different places."
MEDSBIO's goals include maintaining an archive of documentation on standards and proposals for ontologies, software, hardware specifications, web templates and other documentation, as well as an archive of open-source software related to structural biology data-management protocols and an archive of samples and test cases related to those protocols.
The consortium also plans to hold annual workshops on issues related to structural biology data management.
Tripos Directors Reaffirm Plan to Explore M&A, Divestiture
Tripos' board of directors has "reaffirmed [its] commitment" to explore options for spurring growth, including selling or merging the firm, going private, or separating its informatics and research businesses.
The board made the announcement during the company's annual stockholders' meeting on Wednesday. Also at the meeting, the firm's six directors were re-elected to another one-year term, and the board extended the 1996 Director Stock Compensation Plan.
Tripos has been exploring options for its future since at least January, when the company said it had retained financial advisory firm Seven Hills Partners to identify options to help it grow.
Two months earlier, Tripos announced the end of its lucrative four-year collaboration with Pfizer.
Tethys, Calibrant, Undisclosed Pharma License Teranode XDA
Teranode said that it has added a "top five global pharmaceutical company," as well as Tethys Bioscience and Calibrant Biosystems to its customer list for its Teranode XDA data and workflow-management system.
The company said that several existing customers, including AstraZeneca, Nastech, NIH Chemical Genomics Center, Pfizer, and St. Jude Children's Research Hospital, have all recently expanded their use of the company's technology.
The unnamed pharma company will use XDA to handle lifecycle management of samples and associated data within its pathway research group, the company said.
Tethys will use the system to handle inventory management and assay design, while Calibrant will use it for proteomics data-management as part of its quantitative protein biomarker profiling research.
Inpharmatica Gains ISO 9001 Certification for Admensa Service
Inpharmatica said this week that it has been awarded ISO 9001:2000 quality certification for its Admensa ADME business.
Admensa proprietary software tools, laboratory services, and consulting to enable early selection of compounds "with an optimal balance of drug-like properties," the company said.
Inpharmatica said that the Admensa Interactive module, its in silico optimization platform, has recently been enhanced to offer improved QSAR ADME models, P450 metabolism models, and compound prioritization and selection methods.
Peakadilly to Use GeneGo's MetaCore in Proteomics Research
GeneGo said this week that protein biomarker discovery firm Peakadilly has licensed its MetaCore pathway analysis platform.
The content in MetaCore covers "multiple levels of protein interactions from extra cellular stimuli through signaling to core metabolism," making it suitable for proteomics research, GeneGo said.
Financial terms of the agreement were not disclosed.
Genedata, Novartis Expand Screener Software Agreement
Genedata said this week that it has expanded a collaboration with the Novartis Institutes for Biomedical Research in the area of high-throughput screening analysis.
Under the terms of the expanded collaboration, Novartis will use the Genedata Screener software platform at its sites in Cambridge, Mass., and Basel, Switzerland.
The companies began the software collaboration in 2003.
Additional terms were not disclosed.
University of Dundee's Proteomics Facility to Use GenoLogics' Proteus Software
The proteomics facility in Scotland's University of Dundee will use GenoLogics' Proteus software for laboratory information and scientific data management, the company said this week.
The university's FingerPrints Proteomics Facility provides mass spectrometry resources to academic and industrial researchers.
The facility said it will use the software to "improve the services we offer to our ... internal and external customers in the UK and beyond."
FingerPrints is "particularly interested" in using the Proteus to offer new services, including phosphorylation site mapping.